Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation - Summary - MDSpire

Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation

  • By

  • Marco Salvini

  • Fabrizio Maggi

  • Camilla Damonte

  • Lorenzo Mortara

  • Antonino Bruno

  • Barbara Mora

  • Marco Brociner

  • Roberta Mattarucchi

  • Alessia Ingrassia

  • Davide Sirocchi

  • Benedetta Bianchi

  • Stefania Agnoli

  • Matteo Gallazzi

  • Michele Merli

  • Andrea Ferrario

  • Raffaella Bombelli

  • Daniela Barraco

  • Andreina Baj

  • Lorenza Bertù

  • Paolo A. Grossi

  • Francesco Passamonti

  • October 11, 2021

  • 0 min

Share

Objective:

To evaluate humoral and cellular immune response to anti-SARS-CoV-2 vaccination in adult patients with hematological malignancies who underwent autologous stem cell transplantation (ASCT).

Key Findings:
  • 87% of patients developed a humoral immune response with a median Ab titer of 747 BAU/ml.
  • 3% of ASCT-LT patients and 21% of No-ASCT-LT patients did not show detectable antibodies.
  • Being on active treatment and not having ASCT as the last treatment were significantly associated with vaccination failure.
  • Cell-mediated immunity showed lower spike-specific T-cell responses in seronegative patients compared to seropositive patients.
Interpretation:

The study indicates that while a majority of patients with hematological malignancies develop an immune response to the Comirnaty vaccine, those on active treatment or without recent ASCT are at higher risk for vaccination failure.

Limitations:
  • Single-center study may limit generalizability, potentially affecting the applicability of findings.
  • Small sample size for certain subgroups may limit the robustness of conclusions.
  • Follow-up duration may not capture long-term immune responses, impacting the understanding of vaccine efficacy.
Conclusion:

The Comirnaty vaccine elicits a significant immune response in most patients with hematological malignancies post-ASCT, but factors such as ongoing treatment can negatively impact vaccine efficacy, highlighting the need for tailored vaccination strategies.

Original Source(s)

Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation

  • by Marco Salvini, Fabrizio Maggi, Camilla Damonte, Lorenzo Mortara, Antonino Bruno, Barbara Mora, Marco Brociner, Roberta Mattarucchi, Alessia Ingrassia, Davide Sirocchi, Benedetta Bianchi, Stefania Agnoli, Matteo Gallazzi, Michele Merli, Andrea Ferrario, Raffaella Bombelli, Daniela Barraco, Andreina Baj, Lorenza Bertù, Paolo A. Grossi, Francesco Passamonti

  • October 11, 2021

Related Content

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

Anatomy-aware lymphoma lesion detection in whole-body PET/CT

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside